Alternative donor hematopoietic stem cell transplantation for sickle cell disease in Europe.
Adolescent
Adult
Aged
Anemia, Sickle Cell
/ mortality
Child
Child, Preschool
Disease-Free Survival
Europe
/ epidemiology
Female
Graft vs Host Disease
/ etiology
Hematopoietic Stem Cell Transplantation
Humans
Lymphocyte Depletion
Male
Middle Aged
Survival Rate
Transplantation Conditioning
Unrelated Donors
Alternative donor HSCT
Haploidentical HSCT
Sickle cell disease
Unrelated donor HSCT
Journal
Hematology/oncology and stem cell therapy
ISSN: 2589-0646
Titre abrégé: Hematol Oncol Stem Cell Ther
Pays: Saudi Arabia
ID NLM: 101468532
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
31
10
2019
accepted:
11
12
2019
pubmed:
24
3
2020
medline:
27
3
2021
entrez:
24
3
2020
Statut:
ppublish
Résumé
Allogeneic hematopoietic stem cell transplantation (HSCT) is, to date, the only curative treatment for sickle cell disease (SCD). Because an human leukocyte antigen (HLA)-matched sibling donor is not always available, alternative stem cell sources such as unrelated or haploidentical related donors have been explored. To date, few series of SCD patients transplanted with an unrelated donor, cord blood, and haploidentical related donor have been reported, but the high rates of rejection and chronic graft versus host disease have limited their widespread application. We describe the outcomes of a retrospective, registry-based, survey on 144 alternative donor HSCT performed for SCD in 30 European Society for Blood and Marrow Transplantation centers between 1999 and 2017. Data on 70 unrelated adult donors (49%), six cord blood (4%), and 68 haploidentical donors (47%; including post-HSCT Cy, ex vivo T-cell depleted, and other haplo-HSCTs) were reported and missing information was updated by the centers. Overall, 16% patients experienced graft failure, Grade II-IV acute GVHD at 100 days was 24%, whereas Grade III-IV was 10%. Chronic GVHD was observed in 24% (limited for 13 patients and extensive for 18 patients). Overall, the 3-year overall survival (OS) was 86% ± 3% and 3-year event-free survival (EFS; considering death and graft failure as events) was 72% ± 4%. We therefore conclude that alternative donor HSCT for SCD can be feasible but efforts in decreasing relapse and GVHD should be promoted to increase its safe and successful utilization. Moreover, a better knowledge of HLA matching and the tailoring of conditioning could help improve EFS and OS.
Identifiants
pubmed: 32201153
pii: S1658-3876(20)30034-0
doi: 10.1016/j.hemonc.2019.12.011
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
181-188Informations de copyright
Copyright © 2020 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.